Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis

Table 2

Characteristics of included studies for treatment response to EGFR-TKIs.

Author	Year	ORR^#	Non-ORR^#	DCR^&	Non-DCR^&	Response criteria
Zheng L	2013	3/33	18/69	12/77	9/25	RECIST v1.1
Isobe K	2014	8/37	5/20	13/52	0/5	NR
Zhao MC	2014	4/99	12/51	10/122	6/28	RECIST v1.1
Lee JY cohort 1	2015	29/146	3/27	30/163	2/10	RECIST v1.1
Lee JY cohort 2	2015	7/45	3/14	10/55	0/4	RECIST v1.1
Cardona AF	2016	5/55	9/20	NR	NR	NR
Sun S	2017	16/63	17/37	31/97	2/3	RECIST v1.1
Qian K	2017	4/27	10/41	12/63	2/5	RECIST
Wang F	2019	4/64	14/83	14/137	4/10	RECIST v1.0
Incharoen P	2019	13/41	7/36	18/65	2/12	RECIST v1.1
Liu SY CTONG0901	2020	12/97	10/75	20/152	2/20	NR
Liu SY GLCI	2020	13/71	11/46	22/113	2/4	NR
Ariyasu R	2020	22/117	5/23	NR	NR	RECIST v1.1
Li XZ	2021	7/62	18/56	22/106	3/12	RECIST v1.1

^#Number of patients who achieved objective response (ORR) and who did not achieve objective response (non-ORR) in the BIM deletion group/wild-type group, respectively. ^&Number of patients who achieved disease control (DCR) and who did not achieve disease control (non-DCR) in the BIM deletion group/wild-type group, respectively. ORR: objective response rate; DCR: disease control rate; RECIST: Response Evaluation Criteria in Solid Tumors; NR: not reported.